AI-Powered Regulatory Intelligence & Submission Automation for Pharma and MedTech
Regulatory teams in pharma and medical device companies manage a growing information problem. Product documentation, clinical evidence, safety information, labelling, quality records, health authority correspondence and market-specific requirements run to thousands of documents across several systems and geographies.
Most regulatory workflows still depend on manual document review, spreadsheets, email coordination and the knowledge held by a handful of specialists.
AI-assisted regulatory intelligence and submission automation connects that fragmented information into a searchable, increasingly automated regulatory workflow. It also closes the loop with pharmacovigilance and post-market surveillance, where much of the evidence a submission depends on is generated.
The Problem: Regulatory Complexity Continues To Grow
Bringing a product to market and keeping it there requires regulatory teams to coordinate information across clinical, quality, safety, medical, manufacturing and product functions. For companies operating globally the load multiplies.
A regulatory change in one market can affect labelling, clinical evidence requirements, technical documentation, post-market obligations and future submissions. Someone has to work out what changed, which products are affected, which documents need to be updated and who has to act.
Submission preparation adds another layer. Regulatory professionals spend a large share of their time locating source information, comparing document versions, checking consistency, identifying missing evidence and coordinating reviews across stakeholders.
The problem is not document generation. It is understanding regulatory change and translating it into controlled action across the product lifecycle.
The Technology Solution
A regulatory intelligence platform continuously organises and analyses regulatory requirements, internal product documentation, submission history, health authority correspondence and relevant external regulatory information.
Generative AI and natural language processing help teams identify changes, summarise requirements, retrieve supporting evidence, compare documents, detect inconsistencies and prepare controlled first drafts of regulatory content, each draft traceable to the source documents it was built from.
The flow: Regulatory requirement changes → Affected products identified → Impact assessment generated → Relevant documentation retrieved → Required actions recommended → Regulatory team reviews → Submission workflow initiated.
The objective is not autonomous regulatory decision-making. AI is the layer that lets regulatory experts work faster while human review, traceability and governance stay exactly where they are.
Key Capabilities
- Global regulatory change monitoring
- Regulatory intelligence search across internal and external sources
- Product-level regulatory impact assessment
- Submission content drafting assistance with source citations
- Automated evidence retrieval
- Document comparison and gap analysis
- Requirement-to-evidence mapping
- Health authority correspondence intelligence
- Submission readiness assessment
- Cross-document consistency checking
- Regulatory workflow automation
- Human review, approval and audit trails
Business Impact
Regulatory AI reduces the administrative load around information discovery, document preparation, change assessment and submission coordination.
Teams identify relevant regulatory changes earlier, retrieve evidence faster, improve consistency across documentation and spend specialist time on the activities that need regulatory judgment.
For global life sciences organisations that means faster submission preparation, less regulatory workload, better inspection readiness, stronger traceability and a lower risk of missed requirements.
Over time, regulatory intelligence stops being a set of documents and alerts and becomes a connected regulatory knowledge base linking requirements, products, evidence, decisions and actions.
Build Regulatory AI Platforms With Nirmitee
Nirmitee designs and engineers custom regulatory intelligence and submission automation platforms for pharma and biotech and medical device organisations, integrated with existing document, quality, clinical, safety and enterprise systems. Our AI product engineering approach builds the intelligence around your products, workflows, data and governance requirements, with the validation evidence a GxP environment expects.
Turn regulatory complexity into connected, actionable intelligence. Talk to our team about where to start.
Frequently Asked Questions
- Which regulatory sources can the platform monitor?
Public health authority sources such as FDA, EMA, MHRA, PMDA and CDSCO, ICH guidelines, EU MDR and IVDR updates and notified body communications, plus subscribed regulatory intelligence feeds the company already pays for. Internal sources, including the RIM system, previous submissions and health authority correspondence, are indexed alongside them so a change can be matched to the products it affects.
- Can AI draft submission content such as CTD summaries or technical documentation?
It can produce controlled first drafts from source documents, with every statement traceable to its source, and flag gaps where evidence is missing. A regulatory writer reviews, edits and approves. Nothing is submitted without human sign-off, and the draft history is retained for audit.
- How does it fit with our RIM system?
The platform reads documents, metadata and submission history from the RIM system through its API and writes impact assessments, tasks and draft content back. The RIM system remains the system of record; the AI layer sits alongside it rather than replacing it.
- How do we validate an AI tool in a GxP environment?
Risk-based, following GAMP 5 principles: a defined intended use, documented requirements, testing against representative cases, human review of every output that feeds a regulated record, 21 CFR Part 11 controls where electronic records and signatures are created, and periodic performance monitoring after go-live. Model behaviour is versioned so a change can be assessed like any other change.
- How is confidential, unpublished product data protected?
Through private deployment in the company's own cloud or data centre, no use of customer data to train shared models, role-based access mirroring existing document permissions, data residency controls for markets that require them and a complete access log.